27315-07-7

Upstream product

• 823-94-9 2,4,6-trimethyl-s-triazine 
• 608-31-1 2,6-Dichloroaniline 
• 108-77-0 1,3,5-trichloro-2,4,6-triazine 
• 87-62-7 2,6-dimethylaniline 

Downstream Products

• 1335447-82-9 (4-chloro-6-prop-2-ynyloxy-[1,3,5]triazin-2-yl)(2,6-dimethylphenyl)amine 
• 1335447-91-0 N-(2,6-dimethylphenyl)-4-(1-morpholino)-6-(prop-2-ynyloxy)-1,3,5-triazin-2-amine 
• 1335447-92-1 N₂-(2,6-dimethylphenyl)-N₄,N₄-dimethyl-6-(prop-2-ynyloxy)-1,3,5-triazine-2,4-diamine 
• 1335447-57-8 6-((1-(2-(7-chloroquinolin-4-ylamino)ethyl)-1H-1,2,3-triazol-4-yl)methoxy)-N₂-(2,6-dimethylphenyl)-N₄,N₄-dimethyl-1,3,5-triazine-2,4-diamine 
• 1335447-59-0 6-((1-(3-(7-chloroquinolin-4-ylamino)propyl)-1H-1,2,3-triazol-4-yl)methoxy)-N₂-(2,6-dimethylphenyl)-N₄,N₄-dimethyl-1,3,5-triazine-2,4-diamine 

Relevant academic research and scientific papers

S - triazine derivative using the polymerization of the curable composition, the curing and molding material using them (by machine translation)

[Problem] s - triazine derivative using the same molding processability and excellent in storage stability of the polymerizable composition, such as a cured product having excellent heat resistance and productivity of the molding material. (1) Represented by the formula [a], s - triazine derivative polymer. (R1 And R2 Is independently, H, a straight chain alkyl group or branched C1 a-6 // non-substituted aryl group; R1 And R2 The ring may be bonded together to form a; R3 And R4 Is H or a straight-chain alkyl groups are independently C1 a-6/branched; and independently of the linear/branched C1 a-8 A B alkyl group, alkoxy group or halogen atom C1 a-6; n is an integer of 0 - 4 m and are independently; m and n are 2 or more A, each of the substituted benzene ring may condense with B)[Drawing] no (by machine translation)

From human immunodeficiency virus non-nucleoside reverse transcriptase inhibitors to potent and selective antitrypanosomal compounds

The presence of a structural recognition motif for the nucleoside P2 transporter in a library of pyrimidine and triazine non-nucleoside HIV-1 reverse transcriptase inhibitors, prompted for the evaluation of antitrypanosomal activity. It was demonstrated that the structure-activity relationship for anti-HIV and antitrypanosomal activity was different. Optimization in the diaryl triazine series led to 6-(mesityloxy)-N2-phenyl-1,3,5-triazine-2,4-diamine (69), a compound with potent in vitro and moderate in vivo antitrypanosomal activity.

DISUBSTITUTED TRIAZINE DIMERS FOR TREATMENT AND/OR PREVENTION OF INFECTIOUS DISEASES

The present invention relates to novel compounds (I) containing two disubstituted triazine rings covalently linked by an organic linker, thereby creating dimers. These compounds show activity against the causative infective agents of infectious diseases s

DISUBSTITUTED TRIAZINE DIMERS FOR TREATMENT AND/OR PREVENTION OF INFECTIOUS DISEASES

The present invention relates to novel compounds (I) containing two disubstituted triazine rings covalently linked by an organic linker, thereby creating dimers. These compounds show activity against the causative infective agents of infectious diseases s

Synthesis of 4-aminoquinoline-1,2,3-triazole and 4-aminoquinoline-1,2,3-triazole-1,3,5-triazine hybrids as potential antimalarial agents

We report herein synthesis of a series of 4-aminoquinoline-1,2,3-triazole and 4-aminoquinoline-1,2,3-triazole-1,3,5-triazine hybrids and evaluate their antimalarial activity against D6 and W2 strains of Plasmodium falciparum. To study the structure-activi

Trisubstituted 1,3,5,-triazine derivatives

This invention concerns the use of the compounds of formula the N-oxides, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein A is CH, CR4or N; n is 0, 1, 2, 3 or 4; R1and R2are each independently selected from hydrogen, hydroxy, C1-12alkyl, C1-12alkyloxy, C1-12alkylcarbonyl, C1-12alkyloxycarbonyl, aryl, amino, mono- or di(C1-12alkyl)amino, mono- or di(C1-12alkyl)aminocarbonyl wherein each of the aforementioned C1-12alkyl groups may optionally and each individually be substituted; or R1and R2taken together may form pyrrolidinyl, piperidinyl, morpholinyl, azido or mono- or di(C1-12alkyl)aminoC1-4alkylidene; R3is hydrogen, aryl, C1-6alkylcarbonyl, optionally substituted C1-6alkyl; and each R4independently is hydroxy, halo, C1-6alkyl, C1-6alkyloxy, cyano, aminocarbonyl, nitro, amino, trihalomethyl or trihalomethyloxy; L is —X—R5or —X-Alk-R6; wherein R5and R6each independently are indanyl, indolyl or phenyl; each of said indanyl, indolyl or phenyl may be substituted; and X is —NR3—, —NH—NH—, —N═N—, —O—, —S—, —S(═O)— or —S(═O)2—; aryl is optionally substituted phenyl; Het is an optionally substituted aliphatic or aromatic heterocyclic radical; for the manufacture of a medicine for the treatment of subjects suffering from HIV (Human Immunodeficiency Virus) infection. It further relates to new compounds being a subgroup of the compounds of formula (I), their preparation and pharmaceutical compositions comprising them.